ClinicalTrials.gg
CompletedNCT02221869Updated Apr 30, 2019Results posted

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

A Phase 3 interventional study of Xyrem in Narcolepsy With Cataplexy, sponsored by Jazz Pharmaceuticals. Completed at 20 sites in 4 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
9th of 15
106 · median 120
Started
2014
the only one that year
Phase 3
8 of 18
1 open now
Registered
6th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 3, and was the 6th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the efficacy and safety of Xyrem in pediatrics subjects with narcolepsy that includes cataplexy.

03

Conditions studied

  • Narcolepsy With Cataplexy

Browse trials for

04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 7-16 years at Visit 2 for subjects on Xyrem at study entry and at Visit 1.1 for Xyrem-naïve subjects (to ensure subjects are \<18 years of age at the end of the study)
  2. Have a primary diagnosis of narcolepsy with cataplexy that meets International Classification of Sleep Disorders (ICSD)-2 or ICSD-3 criteria, whichever was in effect at the time of the diagnosis or, with the permission of the Medical Monitor, completes a Multiple Sleep Latency Test (MSLT) during Screening to confirm the diagnosis of Type 1 narcolepsy by ICSD-3 criteria (i.e., the subject meets all other ICSD-3 criteria for Type 1 narcolepsy)
  3. Have given documented assent indicating that he/she was aware of the nature of the study and the required procedures and restrictions before participation in any protocol-related activities
  4. Have parent(s)/guardian(s) who have given for his/her/their child's participation in the study
  5. Be willing to spend the required number of nights (2 to 3) in a sleep laboratory for PSG evaluations
  6. If currently treated with Xyrem, must have been taking unchanged doses (twice nightly dosing no higher than 9 g/night) of Xyrem, and stimulants, if applicable, for the treatment of narcolepsy symptoms for at least 2 months prior to screening

In addition to the above inclusion criteria, subjects participating in the PK evaluation must meet the following inclusion criteria:

  1. Be willing to spend 2 additional nights in the clinic for PK evaluation

Exclusion criteria

-

Exclusion Criteria:

  1. Inability to understand assent or follow study instructions for any reason, in the opinion of the Investigator
  2. Parent(s) or guardian(s) unable to comply with the requirements of the study for any reason, in the opinion of the Investigator
  3. Other documented condition (including an unstable medical condition, chronic disease other than narcolepsy with cataplexy, or history or presence of another neurological disorder) that might affect the subject's safety and/or interfere with the conduct of the study in the opinion of the Investigator
  4. Treatment with benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, diclofenac, valproate, phenytoin, ethosuximide within 2 weeks prior to enrollment (discontinuation for the purpose of study enrollment is permitted only if considered safe by the Investigator and approved by the Medical Monitor)
  5. Treatment with any other medications that have anticataplectic effect (e.g., serotonin-norepinephrine reuptake inhibitors [SNRIs], selective serotonin reuptake inhibitors [SSRIs], or tricyclic antidepressants [TCAs]) within 1 month before Screening
  6. Unsafe for the subject to receive placebo treatment for 2 weeks, in the opinion of the Investigator

In addition to the above exclusion criteria, subjects participating in the PK evaluation must not demonstrate the following:

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Xyrem

    Active Xyrem at a dose ≤9 g/night

    Drug: Xyrem

  • Placebo comparator
    Xyrem Placebo

    Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.

    Drug: Xyrem

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Weekly Number of Cataplexy Attacks

    Double-blind comparison of the change in weekly number of cataplexy attacks from the last 2 weeks of the Stable Dose Period to the 2 weeks of the Double-blind Treatment Period.

    Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)

Secondary outcomes

  1. Clinical Global Impression of Change (CGIc) for Cataplexy Severity

    CGIc for cataplexy severity from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.

    Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)

  2. Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score

    Change in the ESS (CHAD) score from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. In the ESS for children and adolescents (CHAD), certain activities were modified. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.

    Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)

  3. CGIc for Narcolepsy Overall

    CGIc for narcolepsy overall from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.

    Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)

  4. Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period

    The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning. The questions and associated point values are separated into the Physical Health (PHS-10 domain) and Psychosocial Health (PSS-10 domain). The sums of the scores in each domain are standardized using the mean and standard deviation from a normal population (2006 sample). The standardized scores are transformed to norm based scoring (NBS) metric. Through NBS, scale scores are standardized to a mean of 50 and SD of 10 in the combined U.S. general population and clinical samples. NBS scores are reported

    Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)

07

Results

Posted Apr 30, 2019

Participant flow

106 subjects were enrolled. Xyrem-naïve subjects (n=74) entered the Dose Titration Period (3 to 10 weeks). Xyrem-naïve and on Xyrem subjects (n= 99) entered the Stable Dose Period (2 to 3 weeks). 96 subjects then entered the Double-Blind Randomized Withdrawal Period (2 weeks). 95 subjects then entered the Open-label Safety Period (38 to 47 weeks).

Participant flow — Overall Study
MilestoneRandomized to XyremRandomized to Xyrem PlaceboOpen-label Xyrem
Started313243
Completed303233
Not completed1010

Outcome measures

PrimaryChange in Weekly Number of Cataplexy Attacks

Double-blind comparison of the change in weekly number of cataplexy attacks from the last 2 weeks of the Stable Dose Period to the 2 weeks of the Double-blind Treatment Period.

Time frame:
From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Reported as:
Median · number of attacks
Change in Weekly Number of Cataplexy Attacks
number of attacksXyremXyrem Placebo
Change in Weekly Number of Cataplexy Attacks0.27 (-1.00 to 2.50)12.71 (3.44 to 19.77)
SecondaryClinical Global Impression of Change (CGIc) for Cataplexy Severity

CGIc for cataplexy severity from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.

Time frame:
From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Reported as:
Mean · score on a scale
Clinical Global Impression of Change (CGIc) for Cataplexy Severity
score on a scaleXyremXyrem Placebo
Clinical Global Impression of Change (CGIc) for Cataplexy Severity-0.4 ± 1.12-1.5 ± 1.19
SecondaryChange in the Epworth Sleepiness Scale (ESS) (CHAD) Score

Change in the ESS (CHAD) score from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. In the ESS for children and adolescents (CHAD), certain activities were modified. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.

Time frame:
From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Reported as:
Median · score on a scale
Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score
score on a scaleXyremXyrem Placebo
Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score0.0 (-1.0 to 2.0)3.0 (1.0 to 5.0)
SecondaryCGIc for Narcolepsy Overall

CGIc for narcolepsy overall from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.

Time frame:
From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Reported as:
Mean · score on a scale
CGIc for Narcolepsy Overall
score on a scaleXyremXyrem Placebo
CGIc for Narcolepsy Overall-0.4 ± 0.95-1.4 ± 1.13
SecondaryChange in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period

The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning. The questions and associated point values are separated into the Physical Health (PHS-10 domain) and Psychosocial Health (PSS-10 domain). The sums of the scores in each domain are standardized using the mean and standard deviation from a normal population (2006 sample). The standardized scores are transformed to norm based scoring (NBS) metric. Through NBS, scale scores are standardized to a mean of 50 and SD of 10 in the combined U.S. general population and clinical samples. NBS scores are reported

Time frame:
From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Reported as:
Median · score on a scale
Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period
score on a scaleXyremXyrem Placebo
SF-10 Physical Summary Score0 (-2.730 to 2.500)0 (-8.420 to 2.730)
SF-10 Psychosocial Summary Score0 (-6.240 to 2.680)-2.670 (-8.020 to 2.670)

Adverse events

Collected over Safety data are provided through the 120 day update.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population0/104 (0%)2/104 (1.9%)80/104 (76.9%)
Randomized Placebo0/32 (0%)0/32 (0%)10/32 (31.3%)
Most frequent serious events
Most frequent serious events
EventSafety PopulationRandomized Placebo
Acute PsychosisPsychiatric disorders1/1040/32
Suicidal IdeationPsychiatric disorders1/1040/32
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSafety PopulationRandomized Placebo
SomnolenceNervous system disorders2/1047/32
EnuresisRenal and urinary disorders20/1041/32
NauseaGastrointestinal disorders20/1040/32
CataplexyNervous system disorders2/1046/32
VomitingGastrointestinal disorders19/1040/32
HeadacheNervous system disorders18/1040/32
Weight decreasedInvestigations12/1041/32
Decreased appetiteMetabolism and nutrition disorders9/1040/32
NasopharyngitisInfections and infestations9/1040/32
Upper respiratory tract infectionInfections and infestations9/1040/32

Baseline characteristics

106 subjects were enrolled. 63 subjects were randomized during the Double-blind Treatment Period. 106 subjects comprised the Enrolled population, and 63 subjects comprised the Efficacy population.

Age, Categorical
Age, Categorical(Participants)Enrolled PopulationPlacebo (Efficacy Population)Xyrem (Efficacy Population)Total
Enrolled Population — <=18 years106——106
Enrolled Population — Between 18 and 65 years0——0
Enrolled Population — >=65 years0——0
Efficacy Population — <=18 years—323163
Efficacy Population — Between 18 and 65 years—000
Efficacy Population — >=65 years—000
Sex: Female, Male
Sex: Female, Male(Participants)Enrolled PopulationPlacebo (Efficacy Population)Xyrem (Efficacy Population)Total
Enrolled Population — Female430—43
Enrolled Population — Male630—63
Efficacy Population — Female—151328
Efficacy Population — Male—171835
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enrolled PopulationPlacebo (Efficacy Population)Xyrem (Efficacy Population)Total
Enrolled Population — Hispanic or Latino6——6
Enrolled Population — Not Hispanic or Latino100——100
Enrolled Population — Unknown or Not Reported0——0
Efficacy Population — Hispanic or Latino—202
Efficacy Population — Not Hispanic or Latino—303161
Efficacy Population — Unknown or Not Reported—000
Region of Enrollment
Region of Enrollment(Participants)Enrolled PopulationPlacebo (Efficacy Population)Xyrem (Efficacy Population)Total
Netherlands8008
United States62——62
Italy25——25
France10——10
Finland1——1
Region of Enrollment
Region of Enrollment(participants)Enrolled PopulationPlacebo (Efficacy Population)Xyrem (Efficacy Population)Total
Netherlands—325
United States—171633
Italy—9918
France—347
08

Study locations

20 sites
  • Miller Children's Hospital - Long Beach
    Long Beach, California 90806, United States
  • SDS Clinical Trials, Inc.
    Orange, California 92868, United States
  • Stanford Sleep Medicine Center
    Redwood City, California 94063, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • The U-M Sleep Disorders Center
    Ann Arbor, Michigan 48109, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Duke Children's Hospital
    Durham, North Carolina 27710, United States
  • ARSM Research, LLC
    Huntersville, North Carolina 28078, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • SleepMed of SC
    Columbia, South Carolina 29201, United States
  • Greenville Health System
    Greenville, South Carolina 29615, United States
  • UT/LeBonheur Neuroscience Institute
    Memphis, Tennessee 38105, United States
  • Todd Swick, MD, PA
    Houston, Texas 77063, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital Robert Debre
    Paris, 75019, France
  • Dipartimento di Scienze Biomediche e Biomotorie
    Bologna, 40139, Italy
  • Sleep Wake Center SEIN Heemstede
    Heemstede, Noord Holland 2103 SW, Netherlands
09

References and documents

Publications

  • Lecendreux M, Plazzi G, Dauvilliers Y, Rosen CL, Ruoff C, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. J Clin Sleep Med. 2022 Sep 1;18(9):2217-2227. doi: 10.5664/jcsm.10090. PubMed 35689598 ↗
  • Wang YG, Menno D, Chen A, Steininger TL, Morris S, Black J, Profant J, Johns MW. Validation of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years. Sleep Med. 2022 Jan;89:78-84. doi: 10.1016/j.sleep.2021.11.003. Epub 2021 Nov 11. PubMed 34920345 ↗
  • Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018 Jul;2(7):483-494. doi: 10.1016/S2352-4642(18)30133-0. Epub 2018 May 21. PubMed 30169321 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Feb 2017, 28 months.

Results were first posted in Apr 2019, 2 years 2 months after primary completion. A results delay was requested in Jan 2018.

Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2014
First posted
Aug 21, 2014
StartActual
Oct 1, 2014
Primary completionActual
Feb 2017
CompletionActual
Jan 25, 2019
Results delay requested
Jan 19, 2018
Results first posted
Apr 30, 2019
Last update
Apr 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02221869
Responsible party
Sponsor
First posted
Aug 21, 2014
Start date
Oct 1, 2014
Primary completion
Feb 2017
Completion
Jan 25, 2019
Results posted
Apr 30, 2019
Last update
Apr 30, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Oxybate

Start the discussion